{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["favezelimab/pembrolizumab"]],"indication":"PD-(L)1-refractory relapsed or refractory classical Hodgkin lymphoma","name":"KEYFORM-008","nct_id":"NCT05508867","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keyform-008-nct05508867. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.","label":"Favezelimab/Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive physician's choice of EITHER bendamustine by IV infusion at a dose between 90 and 120 mg/m\\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose between 800 and 1200 mg/m\\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.","label":"Chemotherapy (Bendamustine or Gemcitabine)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-01-08","type":"ACTUAL"},"conditions":["Hodgkin Lymphoma"],"enrollment":{"count":203,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"favezelimab/pembrolizumab","otherNames":["MK-4820A"],"type":"BIOLOGICAL"},{"name":"bendamustine","otherNames":["BENDEKA®"],"type":"DRUG"},{"name":"gemcitabine","otherNames":["GEMZAR®"],"type":"DRUG"}],"last_update":"2026-09-01","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 2 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-09-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) Per Lugano Response Criteria as Assessed by Investigator","timeFrame":"Up to approximately 34 months"}],"references":[],"start_date":{"date":"2022-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","url":"https://clinicaltrials.gov/study/NCT05508867"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keyform-008-nct05508867"}